Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV000165509 | SCV000216241 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-05-26 | criteria provided, single submitter | clinical testing | The p.N2346S variant (also known as c.7037A>G and 7265A>G), located in coding exon 13 of the BRCA2 gene, results from an A to G substitution at nucleotide position 7037. The asparagine at codon 2346 is replaced by serine, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 6503 samples (13006 alleles) with coverage at this position. To date, this alteration has been detected with an allele frequency of approximately 0.001% (greater than 105000 alleles tested) in our clinical cohort. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of p.N2346S remains unclear. |
| Counsyl | RCV000031662 | SCV000784996 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2017-03-14 | criteria provided, single submitter | clinical testing | |
| Sharing Clinical Reports Project |
RCV000031662 | SCV000054269 | uncertain significance | Breast-ovarian cancer, familial, susceptibility to, 2 | 2011-06-20 | no assertion criteria provided | clinical testing |